AxoGen announces commercial release, first clinical implant of Avive
AxoGen announced the commercial release and first clinical implant of Avive Soft Tissue Membrane. Avive Soft Tissue Membrane is a minimally processed human umbilical cord membrane delivering the benefits of amnion to reduce inflammation and scar tissue formation. Avive represents AxoGen's fourth surgical product and may be used in conjunction with nerve surgery techniques to proactively reduce inflammation and scarring. With the addition of the market opportunity for Avive, the company now estimates that the current addressable market of AxoGen's nerve product portfolio has increased from $1.6B-$1.8B. The company also announced that its salesforce has increased to 51 representatives, up from 45 at the beginning of November, supporting the continued penetration of AxoGen's solutions in the peripheral nerve repair market.